Company: DARE
Filing Date: 2025-04-11
Form Type: 8-K
Source: 0001641172-25-003887
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-11
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On April 9, 2025, Daré Bioscience, Inc. (“ Daré,”
the “ Company,” “we,” “us” or “our”), received a letter from The Nasdaq Stock Market LLC
(“ Nasdaq”) informing us that the Nasdaq Hearings Panel (the “ Panel”) determined to grant our request for an extension
until August 12, 2025 to demonstrate compliance with Nasdaq Listing Rule 5550(b) by demonstrating compliance with either Nasdaq Listing
Rule 5550(b)(1) or 5550(b)(2). Nasdaq Listing Rule 5550(b)(1) requires a company to maintain stockholders’ equity of at least $2.5
million, which we refer to as the “ Stockholders’ Equity Rule,” and Nasdaq Listing Rule 5550(b)(2) requires a company
to have a minimum market value of listed securities of $35.0 million, which we refer to as the “ Minimum MVLS Rule.” A company
will satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b) if it meets either the Stockholders’ Equity Rule
or the Minimum MVLS Rule.

As previously reported, we have not been in compliance
with Nasdaq Listing Rule 5550(b) since August 2024, and we presented our multi-step plan for regaining compliance (“ Plan”)
to the Panel on March 25, 2025. Our Plan includes, among other things, satisfying the Stockholders’ Equity Rule in lieu of the Minimum
MVLS Rule and conducting certain capital raising activities to increase our stockholders’ equity in excess of $2.5 million by April
30, 2025 and to increase it further by July 15, 2025.

The Panel’s determination to grant our request
for an extension is subject to certain conditions, including, among others, that we make progress in executing against our Plan by the
dates specified in our Plan and that on or before August 12, 2025 (a) we publicly disclose transactions we undertook to increase our stockholders’
equity and provide an indication of our stockholders’ equity following such transactions, and (b) we provide the Panel with an update
on our fundraising plans and income projections for the next 12 months. We intend to publicly disclose or provide, as the case may be,
the information required by the Panel’s determination within the timeframe